Polycythemia Vera-Associated Complications: Pathogenesis, Clinical Manifestations, And Effects On Outcomes

References

• Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;(27):1874–1881. doi:10.1038/leu.2013.16323739289
   PubMed Web of Science ®Google Scholar
• Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–375.14820991
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148. doi:10.1038/nature0354615793561
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;15:3472. doi:10.1182/blood-2006-04-018879
   Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391. doi:10.1056/NEJMoa131254224325359
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379. doi:10.1056/NEJMoa131134724325356
   PubMed Web of Science ®Google Scholar
• Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol. 2016;91:50–58. doi:10.1002/ajh.2422126492355
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi:10.1038/s41408-018-0054-y29426921
   PubMed Web of Science ®Google Scholar
• Spivak JL. How I Treat Polycythemia Vera. Blood. 2019;134(4):341–352. doi:10.1182/blood.201883404431151982
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–435. doi:10.1056/NEJMoa140900225629741
   PubMed Web of Science ®Google Scholar
• Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100:4272–4290. doi:10.1182/blood-2001-12-034912393615
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109:68–76. doi:10.1002/cncr.2236517123268
   PubMed Web of Science ®Google Scholar
• Geyer HL, Kosiorek H, Dueck AC, et al. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica. 2017;102:85–93. doi:10.3324/haematol.2016.15880827540137
   PubMed Web of Science ®Google Scholar
• Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–368. doi:10.1016/j.exphem.2014.01.00624463275
   PubMed Web of Science ®Google Scholar
• Vaidya R, Sulai N, Rozell SA, et al. Comprehensive plasma cytokine profiling in polycythemia vera: comparison with myelofibrosis and clinical correlates. Blood. 2011;118:3850. doi:10.1182/blood-2011-02-334870
   Web of Science ®Google Scholar
• Mondet J, Hussein K, Mossuz P. Circulating cytokine levels as markers of inflammation in Philadelphia negative myeloproliferative neoplasms: diagnostic and prognostic interest. Mediators Inflamm. 2015;2015:670580. doi:10.1155/2015/12538026525644
   PubMed Web of Science ®Google Scholar
• Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol. 2013;88(8):665–669. doi:10.1002/ajh.2347423657863
   PubMed Web of Science ®Google Scholar
• Steinman HK. Water-induced pruritus. Clin Dermatol. 1987;5(3):41–48. doi:10.1016/s0738-081x(87)80007-x3311340
   PubMed Web of Science ®Google Scholar
• Jackson N, Burt D, Crocker J, Boughton B. Skin mast cells in polycuthaemia vera: relationship to the pathogenesis and treatment of pruritus. Br J Dermatol. 1987;116:21–29. doi:10.1111/j.1365-2133.1987.tb05787.x3814512
   PubMed Web of Science ®Google Scholar
• Ishii T, Wang J, Zhang W, et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009;113(23):5942–5950. doi:10.1182/blood-2008-09-17941619196660
   PubMed Web of Science ®Google Scholar
• Pieri L, Bogani C, Guglielmelli P, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica. 2009;94(11):1537–1545. doi:10.3324/haematol.2009.00704719608683
   PubMed Web of Science ®Google Scholar
• Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–408. doi:10.1182/blood-2011-02-33487021536863
   PubMed Web of Science ®Google Scholar
• Geyer HL, Andreasson B, Kosiorek HE, et al. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: an analysis by the MPN QOL International Study Group. Cancer. 2016;122(12):1888–1896. doi:10.1002/cncr.3001327070130
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Abels J, Steketee J, et al. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med. 1985;102:466–471. doi:10.7326/0003-4819-102-4-4663977194
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167. doi:10.1186/s12885-016-2208-226922064
   PubMed Web of Science ®Google Scholar
• Wolf BC, Banks PM, Mann RB, Nieman RS. Splenic hematopoiesis in polycythemia vera: a morphologic and immunohistologic study. Am J Clin Pathol. 1988;89:69–75. doi:10.1093/ajcp/89.1.693276145
   PubMed Web of Science ®Google Scholar
• Song MK, Park BB, Uhm JI. Understanding Splenomegaly in Myelofibrosis: association with Molecular Pathogenesis. Int J Mol Sci. 2018;19(3):898. doi:10.3390/ijms19030898
   Web of Science ®Google Scholar
• Geyer HL, Scherber RM, Dueck AC, et al. Symptom severity and clinical variables of polycythemia vera patients with splenomegaly, phlebotomy requirements and/or hydroxyurea use: a retrospective evaluation of 1334 patients. Blood. 2014;124:1848.
   Web of Science ®Google Scholar
• Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313–320. doi:10.1055/s-2007-97616517525888
   PubMed Web of Science ®Google Scholar
• Bar-Natan M, Hoffman R. New insights into the causes of thrombotic events in patients with myeloproliferative neoplasms raise the possibility of novel therapeutic approaches. Haematologica. 2019;104(1):3–6. doi:10.3324/haematol.2018.20598930598493
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122:2176–2184. doi:10.1182/blood-2013-03-46015423823316
   PubMed Web of Science ®Google Scholar
• Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120(25):4921–4928. doi:10.1182/blood-2011-09-37651723043069
   PubMed Web of Science ®Google Scholar
• Stein BL, Wiliams DM, Wang NY, et al. Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders. Haematologica. 2010;95(7):1090–1097. doi:10.3324/haematol.2009.01440720133898
   PubMed Web of Science ®Google Scholar
• Stein BL, Rademaker A, Spivak JL, Moliterno AR. Gender and vascular complications in the JAK2 V617F-positive myeloproliferative neoplasms. Thrombosis. 2011;2011:874146. doi:10.1155/2011/87414622084670
   PubMedGoogle Scholar
• Stein BL, Saraf S, Sobol U, et al. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma. 2013;54(9):1989–1995. doi:10.3109/10428194.2012.75965623245211
   PubMed Web of Science ®Google Scholar
• How J, Zhou A, Oh ST. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. Ther Adv Hematol. 2017;8(3):107–118. doi:10.1177/204062071668033328246554
   PubMed Web of Science ®Google Scholar
• Colaizzo D, Tiscia GL, Bafunno V, et al. Sex modulation of the occurrence of jak2 v617f mutation in patients with splanchnic venous thrombosis. Thromb Res. 2011;128(3):233–236. doi:10.1016/j.thromres.2011.03.02421497883
   PubMed Web of Science ®Google Scholar
• Du Clos TW. Pentraxins: structure, function, and role in inflammation. ISRN Inflamm. 2013;2013:379040. doi:10.1155/2013/37904024167754
   PubMedGoogle Scholar
• Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315–318. doi:10.3324/haematol.2010.03107021173097
   PubMed Web of Science ®Google Scholar
• Lussana F, Carobbio A, Salmoiraghi S, et al. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017;10:54. doi:10.1186/s13045-017-0425-z28228104
   PubMed Web of Science ®Google Scholar
• Zhang W, Qi J, Zhao S, et al. Clinical significance of circulating microparticles in Ph− myeloproliferative neoplasms. Oncol Lett. 2017;14(2):2531–2536. doi:10.3892/ol.2017.645928789461
   PubMed Web of Science ®Google Scholar
• Duchemin J, Ugo V, Ianotto JC, Lecucq L, Mercier B, Abrgrall JF. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. Thromb Res. 2010;126(3):238–242. doi:10.1016/j.thromres.2010.06.02520656333
   PubMed Web of Science ®Google Scholar
• Stein BL, McMahon B, Weiss I, Kwaan HC. Tissue-factor bearing microparticles and thrombotic risk in the myeloproliferative neoplasms. Blood. 2012;120:1145.
   Google Scholar
• Taniguchi Y, Tanaka H, Luis EJ, et al. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. Int J Hematol. 2017;106(5):691–703. doi:10.1007/s12185-017-2302-528780601
   PubMed Web of Science ®Google Scholar
• Delgado-Rizo V, Martínez-Guzmán MA, Iñiguez-Gutierrez L, et al. Neutrophil extracellular traps and its implications in inflammation: an overview. Front Immunol. 2017;8:81. doi:10.3389/fimmu.2017.0008128220120
   PubMed Web of Science ®Google Scholar
• Wolach O, Sellar RS, Martinod K, et al. Thrombosis in myeloproliferative neoplasms is linked to increased Neutrophil Extracellular Trap (NET) formation. Blood. 2016;128:633. doi:10.1182/blood-2016-06-724161
   Web of Science ®Google Scholar
• Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436):eaan8292. doi:10.1126/scitranslmed.aao449629643232
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J, et al. International Working Group For Myelofibrosis Research And Treatment (IWG-MRT). Leukemia. 2008;22:437–438. doi:10.1038/sj.leu.240491417728787
   PubMed Web of Science ®Google Scholar
• Passamonti F, Alessandro V, Domenica C, et al. A new international multicenter‐based model to predict survival in myelofibrosis secondary to polycythemia and thrombocythemia: the mysec prognostic model (MYSEC‐PM). Blood. 2014;124:1826.
   Web of Science ®Google Scholar
• Cerquozzi S, Tefferi A. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015;5:e366. doi:10.1038/bcj.2015.9526565403
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117(10):755–761. doi:10.1016/j.amjmed.2004.06.03215541325
   PubMed Web of Science ®Google Scholar
• Bai J, Ai L, Zhang L, Yang F, Zhou Y, Xue Y. Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. Am J Hematol. 2015;90(12):1116–1121. doi:10.1002/ajh.2419126370613
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Caramella M, et al. A dynamic prognostic model to predict survival in post–polycythemia vera myelofibrosis. Blood. 2008;111:3383–3387. doi:10.1182/blood-2007-11-12143418187660
   PubMed Web of Science ®Google Scholar
• Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol. 2007;138(3):354–358. doi:10.1111/j.1365-2141.2007.06674.x17614822
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Schwager SM, et al. The clinical phenotype of wild‐type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer. 2006;106:631–635. doi:10.1002/cncr.2173016369984
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840–846. doi:10.1182/blood-2006-12-06428717379742
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574–1579. doi:10.1038/leu.2010.14820631743
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21–30. doi:10.1182/bloodadvances.201600021629296692
   PubMed Web of Science ®Google Scholar
• Senín A, Fernández-Rodríguez C, Bellosillo B. Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. Ann Hematol. 2018;97(3):443–451. doi:10.1007/s00277-017-3193-529181548
   PubMed Web of Science ®Google Scholar
• Mesa RA, Verstovsek S, Cervantes F, et al. International Working Group for Myelofibrosis Research and Treatment (IWG- MRT). Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737–740. doi:10.1016/j.leukres.2006.12.00217210175
   PubMed Web of Science ®Google Scholar
• Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms: a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 2017;92:1118–1128. doi:10.1016/j.mayocp.2017.05.01028688466
   PubMed Web of Science ®Google Scholar
• Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera. An analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664–2670. doi:10.1182/blood-2004-09-342615585653
   PubMed Web of Science ®Google Scholar
• Beer PA, Delhommeau F, Lecouédic JP, et al. Two routes to leukemic transformation following a JAK2 mutation–positive myeloproliferative neoplasm. Blood. 2010;115(14):2891–2900. doi:10.1182/blood-2009-08-23659620008300
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29:3907–3913. doi:10.1200/JCO.2011.36.079221911721
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–2232. doi:10.1200/JCO.2005.07.06215710945
   PubMed Web of Science ®Google Scholar
• Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29:2410–2415. doi:10.1200/JCO.2011.34.754221537037
   PubMed Web of Science ®Google Scholar